520 related articles for article (PubMed ID: 33028132)
1. A pharmacist's review of the treatment of systemic light chain amyloidosis.
Hughes DM; Staron A; Sanchorawala V
J Oncol Pharm Pract; 2021 Jan; 27(1):187-198. PubMed ID: 33028132
[TBL] [Abstract][Full Text] [Related]
2. Daratumumab, pomalidomide, and dexamethasone as a bridging therapy to autologous stem cell transplantation in a case of systemic light-chain amyloidosis with advanced cardiac involvement.
Arnall JR; Usmani SZ; Adamu H; Mishkin J; Bhutani M
J Oncol Pharm Pract; 2019 Jun; 25(4):1021-1025. PubMed ID: 30477388
[TBL] [Abstract][Full Text] [Related]
3. Proteasome inhibitors in AL amyloidosis: focus on mechanism of action and clinical activity.
Jelinek T; Kryukova E; Kufova Z; Kryukov F; Hajek R
Hematol Oncol; 2017 Dec; 35(4):408-419. PubMed ID: 27647123
[TBL] [Abstract][Full Text] [Related]
4. Update on the Contemporary Treatment of Light Chain Amyloidosis Including Stem Cell Transplantation.
Abdallah M; Sanchorawala V
Am J Med; 2022 Apr; 135 Suppl 1():S30-S37. PubMed ID: 35081382
[TBL] [Abstract][Full Text] [Related]
5. Complete remission of both immunoglobulin light chain amyloidosis and psoriasis after autologous hematopoietic stem cell transplantation: A case report.
Chen W; Ren G; Zuo K; Huang X
Medicine (Baltimore); 2018 Dec; 97(50):e13589. PubMed ID: 30558027
[TBL] [Abstract][Full Text] [Related]
6. Daratumumab for the treatment of AL amyloidosis.
Sidiqi MH; Gertz MA
Leuk Lymphoma; 2019 Feb; 60(2):295-301. PubMed ID: 30033840
[TBL] [Abstract][Full Text] [Related]
7. Guidelines for high dose chemotherapy and stem cell transplantation for systemic AL amyloidosis: EHA-ISA working group guidelines.
Sanchorawala V; Boccadoro M; Gertz M; Hegenbart U; Kastritis E; Landau H; Mollee P; Wechalekar A; Palladini G
Amyloid; 2022 Mar; 29(1):1-7. PubMed ID: 34783272
[TBL] [Abstract][Full Text] [Related]
8. Treatment of amyloid light chain cardiac amyloidosis: systematic review and future directions.
Alsomali D; Mohty D; Grogan M; Dispenzieri A; Aljurf M; Kumar S; Gertz MA; Hanbali A; Hashmi SK
Clin Adv Hematol Oncol; 2022 Oct; 20(10):609-618. PubMed ID: 36206073
[TBL] [Abstract][Full Text] [Related]
9. [Treatment of AL amyloidosis in 2012; the benefit of new drugs (bortezomib, thalidomide, and lenalidomide). Summary of published clinical trials].
Adam Z; Sčudla V; Krejčí M; Cermáková Z; Pour L; Král Z
Vnitr Lek; 2013 Jan; 59(1):37-58. PubMed ID: 23428001
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review.
Ehsan H; Rafae A; Masood A; Wahab A; Sana MK; Ansar I; Neupane K; Umar A; Ehsan A; Hashmi H
Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e285-e292. PubMed ID: 34879994
[TBL] [Abstract][Full Text] [Related]
11. The efficacy and safety of bortezomib-based chemotherapy for immunoglobulin light chain amyloidosis: A systematic review and meta-analysis.
Liu B; Bai M; Wang Y; Wang D; Zhao J; Li L; Dong R; Sun S
Eur J Intern Med; 2019 Nov; 69():32-41. PubMed ID: 31447275
[TBL] [Abstract][Full Text] [Related]
12. High-Dose Melphalan and Autologous Peripheral Blood Stem Cell Transplantation in AL Amyloidosis.
Sanchorawala V
Acta Haematol; 2020; 143(4):381-387. PubMed ID: 32248194
[TBL] [Abstract][Full Text] [Related]
13. Daratumumab, lenalidomide and dexamethasone in newly diagnosed systemic light chain amyloidosis patients associated with multiple myeloma.
Kawano Y; Hata H; Takashio S; Tsujita K; Ueda M; Matsuoka M
Br J Haematol; 2022 Aug; 198(3):e38-e41. PubMed ID: 35524546
[No Abstract] [Full Text] [Related]
14. Exploiting endogenous and therapy-induced apoptotic vulnerabilities in immunoglobulin light chain amyloidosis with BH3 mimetics.
Fraser CS; Spetz JKE; Qin X; Presser A; Choiniere J; Li C; Yu S; Blevins F; Hata AN; Miller JW; Bradshaw GA; Kalocsay M; Sanchorawala V; Sarosiek S; Sarosiek KA
Nat Commun; 2022 Oct; 13(1):5789. PubMed ID: 36184661
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for the treatment of light chain amyloidosis.
Chakraborty R; Lentzsch S
Expert Opin Emerg Drugs; 2020 Sep; 25(3):299-317. PubMed ID: 32731778
[TBL] [Abstract][Full Text] [Related]
16. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
17. Elotuzumab in Combination with Lenalidomide and Dexamethasone for Treatment-resistant Immunoglobulin Light Chain Amyloidosis With Multiple Myeloma.
Iqbal SM; Stecklein K; Sarow J; Krabak M; Hillengass J; McCarthy P
Clin Lymphoma Myeloma Leuk; 2019 Jan; 19(1):e33-e36. PubMed ID: 30337238
[No Abstract] [Full Text] [Related]
18. Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis.
Palladini G; Milani P; Malavasi F; Merlini G
Cells; 2021 Mar; 10(3):. PubMed ID: 33806310
[TBL] [Abstract][Full Text] [Related]
19. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
[TBL] [Abstract][Full Text] [Related]
20. Advancements and future trends of immunotherapy in light-chain amyloidosis.
Mahadevia H; Ponvilawan B; Sharma P; Al-Obaidi A; Qasim H; Koyi J; Anwer F; Raza S
Crit Rev Oncol Hematol; 2023 Mar; 183():103917. PubMed ID: 36696931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
